Researchers led by St. Jude Children's Research Hospital scientists have worked out how a crucial cancer-related protein, a "histone writer" called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.
OncoGenex Pharmaceuticals Inc. said apatorsen results from two randomized phase II clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium.
A new study offers a treatment option for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.
AstraZeneca presented data from the confirmatory Phase III SOLO-2 trial demonstrating a statistically significant and clinically meaningful improvement of progression-free survival among patients treated with Lynparza (olaparib) compared to placebo.
Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent.
Amgen announced positive results from a planned overall survival interim analysis of the Phase III head-to-head ENDEAVOR trial.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
Levine Cancer Institute launched the first mobile lung computed tomography unit designed to address lung cancer diagnosis, treatment and survival disparities for rural populations across the Carolinas.
St. Jude Children's Research Hospital is naming the institution's principal research tower after its first medical director, Donald Pinkel.